It has a unique MOA -

https://en.wikipedia.org/wiki/Brilacidin

It has had some clinical success treating oral mucositis and ABSSSI. I'm not sure how much, but it was significant.

https://finance.yahoo.com/quote/IPIX/profile?p=IPIX

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19.

And the government is involved -

http://www.ipharminc.com/press-release/2020/6...herapeutic

http://www.ipharminc.com/press-release

http://www.ipharminc.com/press-release/2020/8...ro-testing